Vijay Pande's VZVC: A Smaller, AI-Native Bet on Biology
TechCrunch reports that Vijay Pande — formerly a managing partner overseeing roughly $4 billion in biotech investments at Andreessen Horowitz — has launched a significantly smaller, AI-native fund called VZVC. In a recent interview, Pande explained the fund's deliberate constraint: rather than spreading capital across dozens of bets, VZVC is taking a far more concentrated approach.
A central theme of Pande's thesis, as described to TechCrunch, is that biology is undergoing a fundamental shift — moving from a traditional "discovery" science toward an "engineering" discipline. According to Pande, this transition is what makes the current moment particularly significant for AI applications in medicine.
Pande also addressed one of the persistent challenges facing the sector: clinical trials. Despite advances in AI-driven drug discovery, he noted that the trial process remains brutally expensive, representing a structural bottleneck that the industry has yet to solve.
On the data side, Pande articulated a clear position regarding how AI can best accelerate medical research. Rather than advocating for proprietary, walled-off datasets, he argued that open, shared datasets are what will actually enable AI to transform medicine at scale. This stance positions VZVC's investment philosophy around collaborative data infrastructure rather than data exclusivity.
The full interview is available via TechCrunch.
Meta Tests Robots for Data Center Operations
Ars Technica has published an inside look at Meta's ongoing initiative to deploy robots within its data centers. According to the report, the company is currently testing robotic systems on tasks that would traditionally be performed by human technicians.
The effort reflects a broader industry interest in automating the physical layer of AI and cloud infrastructure — the hands-on maintenance and operational work that keeps large-scale data centers running. Meta's program, as described by Ars Technica, appears to be in an active testing phase rather than a full deployment, with the company evaluating how robotic systems can reliably handle technician-level responsibilities in that environment.
The full report is available via Ars Technica.
Today's stories highlight two distinct but complementary dimensions of AI's expanding footprint: its growing role in reshaping biotech investment strategy and drug development pipelines, and its increasing integration into the physical infrastructure that powers modern AI systems.